Status:

ACTIVE_NOT_RECRUITING

Microdystrophin Gene Transfer Study in Adolescents and Children With DMD

Lead Sponsor:

Solid Biosciences Inc.

Conditions:

Duchenne Muscular Dystrophy

Eligibility:

MALE

4-17 years

Phase:

PHASE1

PHASE2

Brief Summary

This is a controlled, open-label, single-ascending dose study to evaluate the safety and tolerability of SGT-001 in adolescents and children with Duchenne muscular dystrophy (DMD). Participants will r...

Eligibility Criteria

Inclusion

  • Established clinical diagnosis of DMD and documented dystrophin gene mutation predictive of DMD phenotype
  • Confirmed absence of dystrophin as determined by muscle biopsy (ambulatory participants)
  • Anti-AAV9 antibodies below protocol-specified thresholds
  • Stable cardiac and pulmonary function
  • Adolescents: non-ambulatory by protocol-specified criteria
  • Children: ambulatory by protocol-specified criteria
  • Stable daily dose (or equivalent) of oral corticosteroids ≥ 12 weeks

Exclusion

  • Prior or ongoing medical condition or physical examination, ECG or laboratory findings that could adversely affect participant safety, compromise completion of treatment and follow-up, or impair assessment of study results
  • Abnormal liver function
  • Abnormal renal function
  • Clinically significant coagulation abnormalities
  • Impaired cardiovascular function based on cardiac MRI or ECHO
  • Impaired respiratory function based on FVC % predicted or need for daytime ventilatory support
  • Significant spinal deformity or presence of spinal rods
  • Body mass index ≥ 95th percentile for age
  • Exposure to another investigational drug within 3 months or 5 half-lives prior to screening
  • Exposure to drugs affecting dystrophin or utrophin expression within 6 months prior to screening
  • Additional inclusion/exclusion criteria may apply.

Key Trial Info

Start Date :

December 6 2017

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 15 2026

Estimated Enrollment :

12 Patients enrolled

Trial Details

Trial ID

NCT03368742

Start Date

December 6 2017

End Date

October 15 2026

Last Update

December 3 2025

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

David Geffen School of Medicine at UCLA

Los Angeles, California, United States, 90095

2

University of Florida

Gainesville, Florida, United States, 32610